BACKGROUND: The reduced folate carrier (RFC1) is a major methotrexate transporter whose impaired function was recognized as a frequent mechanism of antifolate resistance. Recently, a G80A polymorphism has been described in the RFC1. This study evaluated the effect of the G80A polymorphism in the RFC1 gene on survival and risk of relapse of acute lymphoblastic leukemia. METHODS AND RESULTS: Seventy patients with acute lymphoblastic leukemia were genotyped by polymerase chain reaction restriction fragment length polymorphism method. An association between the polymorphism and risk of relapse was found (P < 0.05). Patients with the G/A genotype have 3.97 (95% confidence interval, 1.12-14.06) and carriers of the A/A genotype have 7.84 (95% confidence interval, 1.66-37.10) higher chance of a relapse. Other variables such as age and leukocyte count were associated (P < 0.05) with the risk of relapse of disease. Individuals with G/A or A/A genotypes had poorer survival (log-rank test, P = < 0.05). CONCLUSIONS: These data suggest a role of the polymorphism G80A in the risk of relapse and the mortality risk in patients with acute lymphoblastic leukemia from the State of Guerrero, Mexico.
BACKGROUND: The reduced folate carrier (RFC1) is a major methotrexate transporter whose impaired function was recognized as a frequent mechanism of antifolate resistance. Recently, a G80A polymorphism has been described in the RFC1. This study evaluated the effect of the G80A polymorphism in the RFC1 gene on survival and risk of relapse of acute lymphoblastic leukemia. METHODS AND RESULTS: Seventy patients with acute lymphoblastic leukemia were genotyped by polymerase chain reaction restriction fragment length polymorphism method. An association between the polymorphism and risk of relapse was found (P < 0.05). Patients with the G/A genotype have 3.97 (95% confidence interval, 1.12-14.06) and carriers of the A/A genotype have 7.84 (95% confidence interval, 1.66-37.10) higher chance of a relapse. Other variables such as age and leukocyte count were associated (P < 0.05) with the risk of relapse of disease. Individuals with G/A or A/A genotypes had poorer survival (log-rank test, P = < 0.05). CONCLUSIONS: These data suggest a role of the polymorphism G80A in the risk of relapse and the mortality risk in patients with acute lymphoblastic leukemia from the State of Guerrero, Mexico.
Authors: Jorge Organista-Nava; Yazmín Gómez-Gómez; Berenice Illades-Aguiar; Luz Del Carmen Alarcón-Romero; Mónica Virginia Saavedra-Herrera; Ana Bertha Rivera-Ramírez; Víctor Hugo Garzón-Barrientos; Marco Antonio Leyva-Vázquez Journal: Oncol Rep Date: 2015-02-06 Impact factor: 3.906
Authors: Yazmín Gómez-Gómez; Jorge Organista-Nava; Carlos Alberto Rangel-Rodriguez; Berenice Illades-Aguiar; María Elena Moreno-Godínez; Luz Del Carmen Alarcón-Romero; Marco Antonio Leyva-Vázquez Journal: Oncol Lett Date: 2014-05-26 Impact factor: 2.967
Authors: Małgorzata Dawidowska; Maria Kosmalska; Łukasz Sędek; Aleksandra Szczepankiewicz; Magdalena Twardoch; Alicja Sonsala; Bronisława Szarzyńska-Zawadzka; Katarzyna Derwich; Monika Lejman; Katarzyna Pawelec; Agnieszka Obitko-Płudowska; Katarzyna Pawińska-Wąsikowska; Kinga Kwiecińska; Andrzej Kołtan; Agnieszka Dyla; Władysław Grzeszczak; Jerzy R Kowalczyk; Tomasz Szczepański; Ewa Ziętkiewicz; Michał Witt Journal: Sci Rep Date: 2016-07-18 Impact factor: 4.379